Literature DB >> 12376059

Advances in Burkholderia cepacia complex.

David Paul Speert1.   

Abstract

Burkholderia cepacia is an important opportunistic pathogen in certain compromised hosts, particularly those with either cystic fibrosis (CF) or chronic granulomatous disease. The "family" of bacteria known as B. cepacia is highly heterogeneous and is composed of at least nine discrete species or genomovars, constituting the B. cepacia complex. Bacteria from the B. cepacia complex are particularly virulent in susceptible hosts, often causing necrotising invasive infection and death. Whereas the microbial determinants of virulence in B. cepacia complex are currently not defined, the bacteria appear to have features facilitating survival within host cells. Burkholderia cepacia is highly resistant to antibiotics and to neutrophil-mediated non-oxidative killing; infection should be treated with combination antimicrobial therapy. Burkholderia cepacia can spread from one CF patient to another. Transmission appears to be facilitated by close personal contact and by certain bacterial factors. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12376059     DOI: 10.1016/s1526-0542(02)00185-9

Source DB:  PubMed          Journal:  Paediatr Respir Rev        ISSN: 1526-0542            Impact factor:   2.726


  29 in total

1.  Dissecting novel virulent determinants in the Burkholderia cepacia complex.

Authors:  George P Tegos; Mark K Haynes; Herbert P Schweizer
Journal:  Virulence       Date:  2012-05-01       Impact factor: 5.882

2.  Antimicrobial activity of CHIR-090, an inhibitor of lipopolysaccharide biosynthesis, against the Burkholderia cepacia complex.

Authors:  Karin Bodewits; Christian R H Raetz; John R Govan; Dominic J Campopiano
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

3.  Bundle-forming pili and EspA are involved in biofilm formation by enteropathogenic Escherichia coli.

Authors:  Cristiano G Moreira; Kelli Palmer; Marvin Whiteley; Marcelo P Sircili; Luiz R Trabulsi; Antonio F P Castro; Vanessa Sperandio
Journal:  J Bacteriol       Date:  2006-06       Impact factor: 3.490

4.  Distribution and expression of the ZmpA metalloprotease in the Burkholderia cepacia complex.

Authors:  S Gingues; C Kooi; M B Visser; B Subsin; P A Sokol
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

5.  Development of a species-specific fur gene-based method for identification of the Burkholderia cepacia complex.

Authors:  Karlene H Lynch; Jonathan J Dennis
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

6.  Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex.

Authors:  Kimberley D Seed; Jonathan J Dennis
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

7.  Cystic fibrosis, a Burkholderia cenocepacia chest wall abscess and rapid clinical deterioration.

Authors:  N J Simmonds; K M Gyi
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

8.  Construction of aminoglycoside-sensitive Burkholderia cenocepacia strains for use in studies of intracellular bacteria with the gentamicin protection assay.

Authors:  Mohamad A Hamad; Alexander M Skeldon; Miguel A Valvano
Journal:  Appl Environ Microbiol       Date:  2010-03-26       Impact factor: 4.792

9.  Role of lipase in Burkholderia cepacia complex (Bcc) invasion of lung epithelial cells.

Authors:  T Mullen; K Markey; P Murphy; S McClean; M Callaghan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

10.  Tyrosine Phosphorylation and Dephosphorylation in Burkholderia cenocepacia Affect Biofilm Formation, Growth under Nutritional Deprivation, and Pathogenicity.

Authors:  Angel Andrade; Faviola Tavares-Carreón; Maryam Khodai-Kalaki; Miguel A Valvano
Journal:  Appl Environ Microbiol       Date:  2015-11-20       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.